Original Article: Allergen-Specific Immunotherapy and Biologics
42 Articles |
-
Long-term changes in milk component immunoglobulins reflect milk oral immunotherapy outcomes in Finnish children
Kauppila, TK, Hinkkanen, V, Savinko, T, et al. Allergy. First published: 15 August 2022
-
A recombinant multimeric dog allergen prevents airway hyperresponsiveness in a model of asthma marked by vigorous TH2 and TH17 cell responses
Stark, J.M., Liu, J., Tibbitt, C.A., et al. Allergy. First published: 03 June 2022
-
Remission of peanut allergy is associated with rewiring of allergen-driven T helper 2-related gene networks
Ashley, SE, Jones, AC, Anderson, D, et al. Allergy. First published: 27 May 2022
-
First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy
Nieto, A., Mazón, Á., Nieto, M., et al. Allergy. First published: 16 May 2022
-
Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference
Sousa-Pinto, B., Schünemann, H.J., Sá-Sousa, A., et al. Allergy. First published: 14 May 2022
-
Cost-effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma
Farraia, M., Paciência, I., Mendes, F.C., et al. Allergy. First published: 22 April 2022
-
Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens
Potapova, E., Bordas-Le Floch, V., Schlederer, T., et al. Allergy. First published: 26 April 2022
-
Allergen Immunotherapy for asthma prevention: a systematic review and meta-analysis of randomised and non-randomised controlled studies
Farraia, M., Paciência, I., Mendes, F.C., et al. Allergy. First published: 28 March 2022
-
A phase 2, randomized multi oral immunotherapy with omalizumab ‘real life’ study
Sindher, S.B., Kumar, D., Cao, S., et al. Allergy. First published: 11 January 2022
-
Determining the minimal important differences in the RQLQ score with grass and tree allergy immunotherapy versus placebo in adults with moderate-to-severe allergy
Blaiss, M.S., Juhl, R.G., Siew, L.Q., et al. Allergy. First published: 05 January 2022
-
A three-stage design for allergen immunotherapy trials
Tang, X., Rabin, R.L., Yan, L.K. Allergy. First published: 02 October 2021
-
Regulatory roles of three miRNAs on allergen mRNA expression in Tyrophagus putrescentiae
Zhou, Y., Li, Q., Pan, R., et al. Allergy. First published: 27 September 2021
-
Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy
Bordas-Le Floch, V, Berjont, N, Batard, T, et al. Allergy. First published: 22 September 2021
-
Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection
Yilmaz, IC, Ipekoglu, EM, Bulbul, A, et al. Allergy. First published: 14 September 2021
-
High dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increase
Hellkvist, L, Hjalmarsson, E, Weinfeld, D, et al. Allergy. First published: 11 August 2021
-
Immunological effects of adjuvanted low-dose allergoid allergen-specific immunotherapy in experimental murine house dust mite allergy
Heldner, A., Alessandrini, F., Russkamp, D., et al. Allergy. First published: 20 July 2021
-
Standardisation of allergen products: 4. Validation of a candidate European pharmacopoeia standard method for quantification of major grass pollen allergen Phl p 5
Wang, S.-H., Zissler, U.M., Buettner, M., et al. Allergy. First published: 09 May 2021
-
RNA viruses in the house dust mite dermatophagoidespteronyssinus, detection in environmental samples and in commercial allergen extracts used for in vivo diagnosis
Vidal-Quist, J.C., Vidal, C., Escolar, F., Lambrecht, B.N., Rombauts, S. and Hernández-Crespo, P.Allergy. First published: 29 April 2021
-
Safety of the standardized quality tree sublingual immunotherapy tablet: Pooled safety analysis of clinical trials
Biedermann, T., Couroux, P., Greve, T.M. and Mäkelä, M. Allergy. First published: 27 April 2021
-
A mathematical model to identify optimal combinations of drug targets for dupilumab poor responders in atopic dermatitis
Miyano, T., Irvine, A.D. and Tanaka, R.J. Allergy.First published: 24 April 2021
-
Adherence to subcutaneous immunotherapy with aeroallergens in real-life practice during the COVID-19 pandemic
Yeğit, O.O., Demir, S., Ünal, D., et al. Allergy. First published: 27 April 2021
-
An exhausted phenotype of TH2 cells is primed by allergen exposure, but not reinforced by allergen-specific immunotherapy
Wang, S.-H., Zissler, U.M., Buettner, M., et al. Allergy. 2021; 76: 2827-2839
-
Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab
Manohar, M., Dunham, D., Gupta, S., et al. Allergy. 2021; 76: 2809-2826
-
Low-affinity but high-avidity interactions may offer an explanation for IgE-mediated allergen cross-reactivity
Chang, X, Zha, L, Wallimann, A, et al. Allergy. 2021; 76: 2565– 2574
-
IgE-cross-blocking antibodies to fagales following sublingual immunotherapy with recombinant Bet v 1
Grilo, J.R., Kitzmüller, C., Aglas, et al. Allergy.2021; 76: 2555-2564
-
β-blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy
Sturm, G.J., Herzog, S.A., Aberer, W., et al. Allergy.2021; 76: 2166-2176
-
Comprehensive mapping of immune tolerance yields a regulatory TNF receptor 2 signature in a murine model of successful Fel d 1-specific immunotherapy using high-dose CpG adjuvant
Leonard, C., Montamat, G., Davril, C., et al. Allergy.2021; 76: 2153-2165
-
Epicutaneous immunotherapy protects cashew-sensitized mice from anaphylaxis
Pelletier, B, Perrin, A, Assoun, N, et al. Allergy. 2021; 76: 1213– 1222
-
Exploring novel systemic biomarker approaches in grass-pollen sublingual immunotherapy using omics
Barker-Tejeda, TC, Bazire, R, Obeso, D, et al. Allergy. 2021; 76: 1199– 1212
-
Laser-facilitated epicutaneous immunotherapy with hypoallergenic beta-glucan neoglycoconjugates suppresses lung inflammation and avoids local side effects in a mouse model of allergic asthma
Korotchenko, E, Schießl, V, Scheiblhofer, S, et al. Allergy. 2021; 76: 210– 222
-
Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis
Nettis, E, Patella, V, Lombardo, C, et al. Allergy. 2020; 75: 2653– 2661
-
Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma
Jutel, M, Brüggenjürgen, B, Richter, H, Vogelberg, C. Allergy. 2020; 75: 2050– 2058
-
Laser-facilitated epicutaneous immunotherapy with depigmented house dust mite extract alleviates allergic responses in a mouse model of allergic lung inflammation
Korotchenko, E, Moya, R, Scheiblhofer, S, et al.Allergy. 2020; 75: 1217– 1228
-
CARsomes inhibit airway allergic inflammation in mice by inducing antigen-specific Th2 cell apoptosis
Zhang, H-P, Sun, Y-X, Lin, Z, et al. Allergy. 2020; 75: 1205– 1216
-
Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation
Le Floc’h, A, Allinne, J, Nagashima, K, et al. Allergy. 2020; 75: 1188– 1204
-
TGFβ1 mimetic peptide modulates immune response to grass pollen allergens in mice
Araujo, GR, Aglas, L, Vaz, ER, et al. Allergy. 2020; 75: 882– 891
-
Alum impairs tolerogenic properties induced by allergoid-mannan conjugates inhibiting mTOR and metabolic reprogramming in human DCs
Benito-Villalvilla, C, Soria, I, Pérez-Diego, M, Fernández-Caldas, E, Subiza, JL, Palomares, O. Allergy. 2020; 75: 648– 659
-
A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens
Huang, H-J, Curin, M, Banerjee, S, et al. Allergy. 2019; 74: 2461– 2478
-
IL-4 receptor α blockade prevents sensitization and alters acute and long-lasting effects of allergen-specific immunotherapy of murine allergic asthma
Russkamp, D, Aguilar-Pimentel, A, Alessandrini, F, et al. Allergy. 2019; 74: 1549– 1560
-
Variability of allergens in commercial fish extracts for skin prick testing
Ruethers, T, Taki, AC, Nugraha, R, et al. Allergy. 2019; 74: 1352– 1363
-
Chemically modified peanut extract shows increased safety while maintaining immunogenicity
van der Kleij, HPM, Warmenhoven, HJM, van Ree, R, et al.Allergy. 2019; 74: 986– 995
-
Der p 1-specific regulatory T-cell response during house dust mite allergen immunotherapy
Boonpiyathad, T, Sokolowska, M, Morita, H, et al. Allergy. 2019; 74: 976– 985
-
Preventive sublingual immunotherapy with house dust mite extract modulates epitope diversity in pre-school children
Ponce, M, Schroeder, F, Bannert, C, et al. Allergy. 2019; 74: 780– 787